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INTRODUCTION and BACKGROUND 
A CDC study shows that one out of nine women in the United States experience 
symptoms of postpartum depression. These numbers also vary by age, race and 
ethnicity. In addition, rates of postpartum depression vary by state, making it as high as 
1 in 5 women with this disorder.1 Postpartum depression (PPD) is a common illness that 
threatens the mental and emotional health of not only a new mother but also the entire 
family. Nonetheless, this disorder has not received the attention it deserves from the 
healthcare community. A mother should not be suffering by herself.  She should have 
the resources and support from the healthcare system so that she can successfully 
overcome the painful emotions associated with PPD. As Richard J. Codey said, 
“Postpartum depression is a very real and very serious problem for many mothers. It 
can happen to a first-time mom or a veteran mother. It can occur a few days…or a few 
months after childbirth”.2 
Awareness of this disorder is necessary for solving this system deficiency.  
Diagnosing it is foremost.  PPD is defined by the DSM-Vi as depressive symptoms that 
must occur within 12 months following parturition. Sadly, many women might not reach 
out to their providers but coverup their symptoms, because of the stigma of depression, 
their feelings of failure as mothers, and their guilt over these negative feelings.3 
Screening for PPD in these patients is vital.  Once this condition is diagnosed, a better 
understanding of the different therapeutic approaches to post-partum depression will aid 
clinicians and patients in selecting an option that is both effective and acceptable to the 
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patient.  Treatment for PPD is not a one-size-fits-all.   Understanding the features of 
PPD can explain the need for individualizing therapy and provide guidance for treatment 
choices.  Clinicians and patients need to work together to surmount this challenging 
disorder.      
While PPD is a common complication, its prevalence varies depending upon the 
report. However, most studies agree that the prevalence ranges between 10% to 16%.4 
Multiple risk factors predispose a mother to PPD. Among those risks are; marital 
conflicts, poor social and financial support during the puerperium, ages < 25 years, 
single-parenting, multiparity, family history of depression or mental illnesses, and 
unintended or unwanted pregnancy. Of all these risk factors, the greatest is a previous 
diagnosis or history of depression in the mother.4,2 
The onset of PPD can vary. Besides, more than 50% will develop symptoms of 
depression before or during pregnancy, whereas over 40% will develop definite PDD 
within the first few months post-delivery. Of the women with PPD, 54% had onset within 
the first month, 40% between 2-4 months, and only 6% from 5 to 12 months.4,3 
 The potential consequences of postpartum depression are significant because 
they affect not just the patient, but also the patient’s family, including her developing 
child, her spouse or partner, her other children, and others in the immediate family.  
Mothers suffering from PPD do not play, read stories, or develop a deep bond with their 
babies. Consequently, the bond between a mother and her baby is impacted.3 Other 
findings in PPD include decreases in breastfeeding, attention to their baby’s sleep 
hygiene and safe positioning, and in vaccination compliance, therefore increasing these 
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infants’ risks for illnesses and injuries. PPD also strains the marriage and other 
relationships. Lastly, although women with PPD have the lowest incidence of suicide or 
infanticide, even one death is a frightening number for any family and society.4 
Therefore, early recognition and treatment of this disorder is critical to avoiding these 
complications. 
Thus, after the diagnosis of PPD, treatment becomes a priority.  The clinician and 
patient need to work as a team to choose a therapy that is appropriate for the severity of 
the symptoms and acceptable to the patient. Among current approaches to the 
treatment of PPD are non-pharmacologic treatments and pharmacologic treatments.  
Non-pharmacologic treatments consist of cognitive behavioral therapy (CBT), 
interpersonal psychotherapy (IPT), nondirective counseling, psychodynamic 
psychotherapy, electroconvulsive therapy (ECT), exercise, acupuncture, and bright-light 
therapy.  Pharmacotherapy consists of antidepressants, ketamine, and brexanolone. 
Antidepressants used are primarily the selective serotonin reuptake inhibitors (SSRIs), 
paroxetine and sertraline. Recommended initial treatment for mild to moderate 
postpartum depression is psychotherapy, but often antidepressants such as SSRIs or 
SNRIs (serotonin-norepinephrine reuptake inhibitors) are used in addition or if the 
patient prefers them.  In women suffering from moderate to severe PPD, the 
recommended treatment is pharmacotherapy with antidepressants, SSRIs, SNRIs, or 
mirtazapine, all of which are considered safe for pregnant and lactating women.3,2 
However, most clinicians simply prescribe SSRIs because of their safety and because it 
is a common practice.4,1 Furthermore, most providers do not separate PPD into 
categories by degree of severity, which omission does not individualize therapy.3,2 
5 
 
Many factors influence treatment success, especially treatment adherence. 
Adhering to any therapy is challenging for a new mother because her time and attention 
are devoted to taking care of her newborn around the clock, thus leaving little reserve 
for taking care of her own needs. However, clinicians must remind patients that a 
successful mother must first care for herself. This factor highlights the importance of 
individualizing therapy and involving the patient in treatment decisions in order to 
optimize adherence.   
In addition to recognizing the integral role of patient adherence, successful 
therapy requires a knowledge of the efficacies of various PPD treatments and a 
familiarity with their potential adverse effects and harmful aspects. The elements of 
treatment options, including non-pharmacologic and pharmacologic therapies, will be 
examined in order to provide clinicians with relevant evidence for medical decision-
making.   
DISCUSSION 
Available research on PPD treatments includes randomized controlled trials 
(RCTs), systematic reviews, meta-analyses, and some case studies. Results varied 
depending on not only the treatment employed, but also the patient’s history of previous 
episodes of major depression, and prior treatments, if any, along with the severity of 
depression, the patient’s compliance with therapy, and her support network.  
Nonpharmacologic Therapies:  
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          Psychotherapeutic interventions have been championed because abnormal 
behaviors typically result from distorted cognition, which is the basis for CBT.  In 
addition, psychotherapy is not burdened by potential adverse effects that 
antidepressants have on either the mother or her breastfeeding infant (via drug 
concentration in breast milk). Experts propose that CBT is beneficial in improving the 
symptoms of postpartum depression.  
A systematic review and meta-analysis by Stephens et al. examined results of 10 
RCTs involving 1324 new mothers in England with PPD. Psychological therapy was 
shown to be effective.  Findings were significant, and no significant differences were 
noted among the different types of psychological treatments.  Furthermore, in some of 
the RCTs, psychological therapy in combination with antidepressants was more 
effective than antidepressants alone.5,2 The authors examined psychological 
interventions in primary care, hence were the first to provide evidence that such 
treatment is viable in that setting. Results of this research were strengthened by the 
inclusion of a sensitivity analysis that removed low quality studies.5,3 Some of the 
weaknesses of this research were that many of the studies had small sample sizes, 
high attrition, and allowed concomitant use of antidepressant medication. Thus, these 
methodologic limitations weakened the conclusions and might have introduced bias.5,3 
Exercise is another, potentially safe treatment option. A systematic review and 
meta-analysis by Pritchett et al. examining 13 RCTs with 1734 participants provided 
evidence that aerobic exercise does improve PDD.  These findings were significant and 
comparable to the improvements seen with antidepressant therapy and with low 
intensity psychological interventions, such as CBT and usual care for PPD. This study 
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also highlighted that many women who have PPD had time constraints to exercise. 
Nonetheless, it can be extrapolated that those who have a robust support system could 
benefit from taking a few hours daily for themselves. 
A study by Dowlati et al. examined another non-pharmaceutical therapy, dietary 
supplementation for improving postpartum blues (PPB). PPB are believed to be the 
prodromal state of postpartum depression and this prodromal state is more prevalent on 
postpartum day five. This dietary supplementation was created to target neurobiological 
changesii in the prodromal state prior to PPD.6 In this double blinded RCT, one group of 
participants (n=21) received the dietary supplement composed of 2 g of tryptophan, 10 
g of tyrosine, and blueberry juice with blueberry extract. The control group (n=20) did 
not receive supplements. The dietary supplement group experienced resolution of 
intense post-partum blues. The large effect size of 2.9 (ten times greater improvement 
as compared with placebo and other interventions) was this study’s strength. Its low-
cost solution was also favorable. However, subjects were assigned based on protocol 
availability instead of an actual randomized double-blind placebo-controlled trial, which 
limits the quality of evidence by introducing bias.6,3 Nonetheless, dietary 
supplementation might be augmented with exercise and psychotherapy. 
Additional nonpharmacologic treatments for PDD and other reproductive 
conditions, such as menstruation and pregnancy, were examined in several studies. 
Therapies included acupuncture, electroconvulsive therapy, bright light treatment, and 
psychological interventions. A double blind RCT explored twice-weekly sessions of 
traditional and sham electro-acupunctureiii for treating PPD in 20 women who had been 
diagnosed with PPD. Even though the sample size was small, participants’ symptoms 
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improved 50 and 44 percent for traditional versus sham electro-acupuncture, 
respectively. Despite participants’ reduction in their symptoms, final results lacked 
statistical significance.3,4 
Bright Light Treatment (BLT) was studied in women who met criteria for PPD. For 
several weeks, the treatment group of ten women received BLT daily while the placebo 
group of five women received a lower intensity light therapy daily, each session lasting 
thirty minutes in each group. Both groups had significant improvements in symptoms 
evidenced by a 49% reduction in SIGH-SADiv scores in each group. Neither study found 
statistically significant differences and this limitation derives from inconsistencies in the 
methodology and also small sample sizes in both groups, hence the evidence was 
inconclusive.3,3 
Postpartum electroconvulsive therapy (ECT) is a therapeutic option for severe 
PDD. The evidence from a systematic review revealed a more rapid improvement of 
depressive symptoms with ECT when compared with the usual antidepressants. Within 
two weeks, 5-7 treatments significantly reduced the severity of depression.7 In a case 
study, a female with severe PPD and a suicide attempt at 38 weeks gestation was 
subsequently admitted to the hospital postpartum with her infant for ECT of her 
previously refractory PPD.7,1 She experienced significant benefits that improved her 
quality of life and bonding with her baby. Notwithstanding the favorable results with 
ECT, its relapse rate exceeds 50% and thus, requires repeated administration for 
relapses. ECT’s adverse effects also need to be considered, and include complications 
such as disorientation after each session, anterograde amnesia for recently learned 
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information, and retrograde amnesia for previously learned information all of these are 
most often transient.7,3 
Pharmacologic Therapies: 
Research has suggested the effectiveness of selective serotonin reuptake 
inhibitors (SSRIs) in treating antidepressant-naïve patients with PPD who were 
unresponsive to CBT or other psychotherapies. Compared to any other class of 
antidepressants, SSRIs have been used more frequently during pregnancy and in 
postpartum women; they have also been studied in breastfeeding women. SSRIs are 
used in ninety percent of women suffering from postpartum depression. Among SSRIs, 
paroxetine or sertraline are most commonly used since adverse effects on infants 
appear to be low and they are not detectable in breastmilk.8  Patients on SSRIs 
compared with those on placebo had a 40% improvement in depression symptoms 
compared with 20% in the placebo group.8,1 Other antidepressants that have been safe 
and effective include the serotonin norepinephrine reuptake inhibitors (SNRIs), 
mirtazapine and the tricyclic antidepressant (TCA), nortriptyline.  PPD symptom 
improvements are similar for SSRIs and SNRIs therapies.8,2  These findings are 
supported by a few head to head RCTs that compared those antidepressants for 
treating PPD and improvement in patients’ depressive symptoms was equivalent among 
these antidepressants.8,4  
Recently, the prophylactic use of ketamine for preventing postpartum depression 
in Chinese women undergoing Cesarean section was examined. Ketamine is a general 
anesthetic that also increases serotonin and melatonin, which effects are generally 
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beneficial.  In this RCT, a total of 654 women were followed, some with antenatal 
depression and some without it.  The treatment and control groups were well-matched. 
The treatment group was given a 0.5 mg/kg dose of ketamine ten minutes after 
Cesarean section, whereas the control group only received standard postpartum care. A 
significant reduction of PPD occurred in the group that received ketamine post-delivery. 
This therapy also decreased PPD in participants who had antenatal depressive 
syndrome and anxiety during pregnancy, both of which are risk factors for PPD. 
Adverse effects, were minor and transient.9   The large group of participants and the 
single-administration of treatment (ensuring compliance) were study strengths.  
Nonetheless, the findings in this study have yet to be reproduced by other investigators.  
Furthermore, ketamine’s mechanism of action for treatment of depression is not fully 
understood. 
Another drug, brexanolone, was approved in 2018 by the FDA for treatment of 
postpartum depression and is considered one of the most effective treatments available 
for moderate to severe PPD. A review article by Powell et al of phase II and III trials 
reported rapid beneficial effects within 72 hours post infusion. However, durability of 
these effects beyond thirty days was questionable.10 Nonetheless, brexanolone was 
efficacious in women with PPD who had moderate to severe symptoms. Some of the 
adverse effects reported were dizziness, somnolence, and headache.10,2 Other less 
common side effects were nausea, rash, postural dizziness, dry mouth and hot flashes. 
Brexanolone has an FDA black box warning for central nervous system depression and 
loss of consciousness. Therefore, it requires administration in a specialized care facility 
as well as enrollment in REMS.v  
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Non-pharmacologic approaches vs pharmacologic approaches and their respective 
outcomes: 
A study compared Interpersonal Therapy (IPT), sertraline-Clinical Management 
(CM) and placebo-CM in the acute treatment of PPD over 12 weeks. In this study, 162 
women who met DSM-IV criteria for postpartum depression and met inclusion criteria 
were enrolled in the randomized treatment phase. Findings did not show significant 
differences between the IPT group and the medication groups.  However, active 
interventions with or without pharmacotherapy delivered for a period greater than twelve 
weeks led to significant improvement in depressive symptoms and improved social 
adjustment in these women suffering from PPD. More importantly, this research 
confirmed that a woman’s treatment preference should be honored whenever possible 
since patient-selected therapy was the major determinant for treatment adherence. It 
also validated the need for well-trained clinicians capable of applying evidence-based 
IPT as well as evidence-based pharmacotherapy for women suffering from PPD.11 The 
double-blind, placebo-controlled trial design was a strength.  In addition, the diversity 
among participants was conducive to generalizability even though the sample size was 
relatively small.  Some participants dropped-out, creating a selection bias, probably 
because they could not enroll in the treatment they desired. 
 In summary, effective treatments for PPD include the following: 
      II.          Data supporting non-pharmacologic therapies 
o The effect of exercise was favorable compared to low intensity 
psychological interventions Such as online CBT and casual care for 
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depression in the general population. These effects are also compared to 
antidepressants 12 
o Psychological interventions are valid and should be tried in women who 
suffer from PPD and do not want to take antidepressant medications.5 
o CBT in short-term and long-term follow up was associated with a better 
Edinburgh Postnatal Depression Scale (EPDS) than no CBT control.13 
o A combination of tryptophan, tyrosine and blueberry extract/juice almost 
completely eliminated the vulnerability to depressed mood during the peak 
period of PPD with an effect size of at least 10-fold greater than the effect 
size reported for other interventions.6 
o Traditional and sham acupuncture both improved symptoms of PPD with 
remission rates of 50% and 44%, respectively.3 
o Response to electroconvulsive therapy was high, especially in patients 
with severe PPD. However, it is not recommended for patients with mild 
depression.14 Significant adverse effects can occur. 
III.          Data supporting pharmacologic therapy 
o SSRIs and SNRIs remain the safest choice for patients who fail CBT or 
other psychotherapies. These antidepressants are also safe for women 
who are breastfeeding.10 
o Sertraline CM induced improvements in PDD more quickly (within eight to 
twelve weeks) than IPT and placebo pill.5 
o Ketamine, when administered before a C-section compared with no 
ketamine, had a prophylactic effect against PPD.12  
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o Brexanolone is effective for the treatment of moderate to severe PPD and 
rapidly reduces PPD symptoms. However, clinicians must be aware of its 
side effects.10 
Choosing the best treatment for each case—these are essential questions to ask: 
1. Does the patient have a history of depression, anxiety, or any other mental 
illness? 
2. Was she treated with CBT, antidepressants, or another approach? 
3. If treated in the past, what was the outcome of treatment? 
4. What is the severity of her depression at the time of assessment? 
5. Were or are any suicidal ideations present? 
CONCLUSION    
The efficacy and safety of various non-pharmacologic and pharmacological 
measures for treating postpartum depression were examined. No singular treatment can 
be considered appropriate for all patients suffering from postpartum depression. 
However, psychological interventions are generally the safest because they have few 
clinical side effects. Low to moderate-intensity exercise, which is generally safe, was 
found to be effective and even superior to low intensity psychological approaches (such 
as online CBT and usual care for depression) and antidepressants.  Medications, in 
particular SSRIs, SNRIs and brexanolone, are effective treatments. Ketamine also 
shows promise for prevention of PPD.  In addition, an array of other treatments has 
been shown to be effective and provide alternatives for patients. Overall, psychological 
intervention is a validated treatment choice in primary care and is an excellent 
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alternative for women who do not want pharmacotherapy. Treatment must be carefully 
selected based on each woman’s preference, her current level of depression, and her 
prior history of depressive disorders. Now clinicians can offer their patients a variety of 
treatments for the treatment of PPD, both pharmacologic and non-pharmacologic.  
Therapies available for this disorder are effective and should be individualized.  
 
Areas for future research include long term follow up to assess the durability of 
treatments, exploring the relationship between Adverse Childhood Events as a risk 
factor for PPD, examining the role of support systems in the development and treatment 
of PPD, and considering the potentially harmful effects of PPD medications on breast-
fed infants.   Future investigations also need to determine whether antidepressants 
when given during pregnancy or post-partum have harmful effects on women’s brains or 
children’s development, and whether early screening identifies patients at risk of 
developing PPD, thereby affording opportunities to prevent it. 
Notwithstanding the need, research in pregnant and post-partum women has 
challenges.  Concern about how therapies may affect the infant as well as the mother 
may discourage participants.  The fatigue and time constraints in this population of 
women make commitment to a study undesirable. Nonetheless, clinicians should 
champion research in this vulnerable population in order to improve women’s health and 
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